Wyeth PFE

  1. All
  2. Commentary
  3. Stock Reports
  4. Fund Reports
  5. ETF Reports
  6. Headlines
    1. CORRECTED-UPDATE 2-Lilly beats forecasts, vows to remain independent


      Thu, 24 Jul 2014

      (Corrects 10th paragraph to show Pfizer bought Warner Lambert, Pharmacia and Wyeth (not Pfizer)

    2. An Inefficient Stock Market Will Catch Up To Progenics


      Mon, 21 Jul 2014

      Relistor can be approved upon submission of a plan for a post marketing study. Relistor has a history. In 2005, Progenics and Wyeth entered into an agreement to develop Relistor. By 2008, subcutaneous Relistor had earned FDA approval for a narrow patient

    3. New Morningstar Analyst Report for Teva Pharmaceutical Industries Ltd

      Stock Reports

      Tue, 24 Jun 2014

      candidates to market could erode cash flows as these existing products face generic competition. Management recently settled with Wyeth (now part of Pfizer) for $1.6 billion over Teva’s at-risk launch--before legal clearance--of generic Protonix

    4. Pfizer: Pfine With Or Without AstraZeneca


      Mon, 23 Jun 2014

      decades has come through the company's numerous acquisitions, most notably Warner-Lambert in 2000, Pharmacia in 2003 and Wyeth in 2009. From the aforementioned key acquisitions or smaller separate acquisitions, Pfizer also includes assets of former

    5. ‘Trying to Recapture the Magic’: The Strategy Behind the Pharma M&A Rush


      Fri, 30 May 2014

      string of big-ticket mergers. It bought Warner-Lambert in 2000 for $90 billion, Pharmacia in 2003 for $60 billion and Wyeth in 2009 for $68 billion. As a result of those mergers, Pfizer found itself saddled with some businesses it didn’t want

    6. New Morningstar Analyst Report for Pfizer Inc

      Stock Reports

      Wed, 28 May 2014

      statements. Pfizer is the world's largest pharmaceutical firm, with annual sales over $50 billion. Following the acquisition of Wyeth , prescription drugs now account for close to 90% of sales. Top sellers include cholesterol-lowering Lipitor, Celebrex

    7. New Morningstar Analyst Report for Zoetis Inc

      Stock Reports

      Mon, 31 Mar 2014

      over the next five years. Zoetis has recently seen margin improvement due to synergies from the acquisitions of Fort Dodge ( Wyeth ) and Alpharma (King Pharma) and from Pfizer's companywide cost-reduction program. Management expects continued margin

    8. Mead Johnson Lowering Prices on Some China Products by 7%-15%; Maintaining Fair Value Estimate


      Wed, 10 Jul 2013

      China by 7%-15%, echoing changes made by competitors Danone BN (decreasing prices by 5%-20%), Nestle NESN (its Wyeth unit, acquired from Pfizer PFE , is lowering prices by 6%-20%), Abbott Laboratories ABT (4%-12%), and local competitors

    9. PPH Market Vectors Pharmaceutical ETF ETF Analysis, Report, Research, 5 Star Rating – Morningstar

      ETF Reports

      Tue, 21 Aug 2012

      individual stocks, you can always be shocked by a bolt from the blue. Think of the challenges raised (and wealth destroyed) with Wyeth 's Fen-phen, Merck's Vioxx, or Boston Scientific's BSX drug-eluting stents. A product can be wildly successful one

    10. Pfizer Reports Strong 2Q as Cost-Cutting Helps Offset Generic Competition to Lipitor


      Tue, 31 Jul 2012

      we believe the majority of the efficiency improvements stem from Pfizer's plan to save $4 billion annually following the Wyeth acquisition. We believe Pfizer is likely to achieve this goal. Additionally, Pfizer reaffirmed its full-year 2012 earnings

    « Prev12345Next »
    Content Partners